Clinical Scorecard: Sura Vec Shows Promise in NPDR
At a Glance
| Category | Detail |
|---|---|
| Condition | Nonproliferative Diabetic Retinopathy (NPDR) without Diabetic Macular Edema (DME) |
| Key Mechanisms | Suprachoroidal anti-VEGF gene therapy using sura vec (surabgene lomparvovec) |
| Target Population | Patients with NPDR at DRSS levels 47 and 53 |
| Care Setting | Ophthalmology clinics |
Key Highlights
- Sura vec demonstrated sustained DRSS improvements over 2 years.
- 42% of control eyes experienced DRSS worsening compared to significantly lower rates in sura vec groups.
- 50% of patients at dose level 3 achieved 2 or more step DRSS improvements at 2 years.
- Safety profile was acceptable with manageable side effects.
- No patients at dose level 3 experienced DRSS worsening from year 1 to year 2.
Guideline-Based Recommendations
Diagnosis
- Assess DRSS levels to determine NPDR severity.
Management
- Consider suprachoroidal injection of sura vec for NPDR patients to prevent progression.
Monitoring & Follow-up
- Regular follow-up on DRSS changes and vision-threatening events.
Risks
- Monitor for conjunctival hyperemia, episcleritis, and intraocular inflammation.
Patient & Prescribing Data
NPDR patients without DME, primarily at DRSS levels 47 and 53.
Sura vec shows potential for durable efficacy and safety with a single suprachoroidal injection.
Clinical Best Practices
- Utilize a short course of topical steroids to mitigate inflammation risks.
- Evaluate patient response to treatment at 1 and 2-year intervals.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.